Compare HWBK & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HWBK | SLGL |
|---|---|---|
| Founded | 1865 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 247.1M |
| IPO Year | 1996 | 2016 |
| Metric | HWBK | SLGL |
|---|---|---|
| Price | $32.62 | $77.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | 3.1K | ★ 10.5K |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | ★ 31.42 | N/A |
| EPS | ★ 3.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $122.71 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.50 | $0.40 |
| 52 Week High | $36.25 | $97.97 |
| Indicator | HWBK | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 41.87 | 48.42 |
| Support Level | $32.33 | $71.01 |
| Resistance Level | $33.71 | $96.99 |
| Average True Range (ATR) | 0.83 | 10.76 |
| MACD | -0.11 | -2.27 |
| Stochastic Oscillator | 6.64 | 25.37 |
Hawthorn Bancshares Inc is a financial holding company that, along with its subsidiary bank, provides commercial banking for small and mid-sized businesses, including equipment, operating, commercial real estate and SBA loans, and personal banking services such as real estate mortgage lending, installment and consumer loans, certificates of deposit, checking, savings and money market accounts. The company also provides trust services including estate planning, investment and asset management services, brokerage and cash management services. Its primary source of revenue is net interest income derived from lending and deposit taking activities, with much of its business in commercial, commercial real estate development and residential mortgage lending.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.